Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Change in Receivables (2016 - 2025)

Marimed (MRMD) has disclosed Change in Receivables for 12 consecutive years, with $441000.0 as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 2421.05% to $441000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $429000.0 through Dec 2025, up 679.73% year-over-year, with the annual reading at $429000.0 for FY2025, 679.73% up from the prior year.
  • Change in Receivables for Q4 2025 was $441000.0 at Marimed, down from $1.3 million in the prior quarter.
  • The five-year high for Change in Receivables was $4.0 million in Q3 2021, with the low at -$1.8 million in Q2 2021.
  • Average Change in Receivables over 5 years is $242300.0, with a median of -$15000.0 recorded in 2022.
  • The sharpest move saw Change in Receivables plummeted 16731.96% in 2021, then soared 21057.14% in 2023.
  • Over 5 years, Change in Receivables stood at $811000.0 in 2021, then crashed by 102.59% to -$21000.0 in 2022, then grew by 9.52% to -$19000.0 in 2023, then changed by 0.0% to -$19000.0 in 2024, then surged by 2421.05% to $441000.0 in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $441000.0, $1.3 million, and -$1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.